GNAO1 as a Novel Predictive Biomarker for Late Relapse in Hepatocellular Carcinoma
Table 1
Relationships between GNAO1 protein level and clinicopathological parameters in 79 HCC patients.
Clinicopathological parameters
Case, n (%)
GNAO1 expression
value
Low (n = 35)
High (n = 44)
Age (years)
<60
62 (78.5)
29
33
0.399
≥60
17 (21.5)
6
11
Sex
Male
66 (83.5)
29
37
0.883
Female
13 (16.5)
6
7
HBV infection
Yes
62 (78.5)
26
36
0.418
No
17 (21.5)
9
8
AFP
<200 ng/mL
30 (38.0)
16
14
0.206
≥200 ng/mL
49 (62.0)
19
30
Liver cirrhosis
Yes
55 (69.6)
26
29
0.421
No
24 (30.4)
9
15
Tumor location
Left lobe
42 (53.2)
16
26
0.237
Right lobe
37 (46.8)
19
18
Maximum tumor size
<30 mm
13 (16.5)
8
5
0.171
≥30 mm
66 (83.5)
27
39
Number of tumors
1
72 (91.1)
32
40
0.751
≥2
7 (8.9)
3
4
Tumor type
Lump
71 (89.9)
30
41
0.473
Nodular
8 (10.1)
5
3
Vascular invasion
Yes
26 (32.9)
11
15
0.802
No
53 (67.1)
24
29
TNM stage (AJCC 8th)
I-II
64 (81.0)
31
33
0.215
III-IV
15 (19.0)
4
11
Abbreviations: HCC: hepatocellular carcinoma, HBV: hepatitis B virus, AFP: alpha-fetoprotein, TNM: tumor-node-metastasis, AJCC: American Joint Committee on Cancer
